Overview
Over the past few decades, biopharmaceuticals have gained significant popularity owing to their therapeutic efficacy, favorable safety profiles and ability to treat a wide variety of disease indications, which are otherwise hard to treat. The success of these interventions has prompted the stakeholders to upgrade the conventional biologics manufacturing equipment. As a result, the domain has witnessed several technological advancements, including the adoption of controllers and automated systems. These systems not only ensure that the processes continue to run within precise limits but also make the necessary adjustments, while minimizing the risk of human errors and improving the product quality. Additionally, these controllers and automation systems have the potential to address a number of challenges associated with traditional bioprocessing systems and offer various additional benefits, such as lowering of production and labor cost (by 20-30%), optimizing the energy consumption (by 5-30%) and increasing the overall productivity (by 10-20%).
Given the various advantages of controllers and automated systems, biopharmaceutical developers and manufacturers are steadily adopting such solutions. Moreover, the recent surge in demand for vaccines amidst the ongoing COVID-19 pandemic has also prompted the biopharmaceutical companies to develop automation systems for producing drugs at a faster pace. In addition, several equipment manufacturers offering more user-friendly, controlled, and automated systems, have emerged. In fact, the field has been witnessing a lot of innovations, evident from the number of patents filed for the controllers and automation systems. These controllers and automated systems use process analytical technological tools that can be easily integrated in the bioprocessing unit to improve scalability. Stakeholders have also been focusing on making further improvements and have incorporated a variety of key features, including provisions for alerts/alarms, built-in system process control sensors, remote monitoring features, visual display, and advanced safety provisions. Owing to the rising interest of stakeholders towards technological advancement and adoption of these systems, we believe that the overall bioreactor controller and automation systems market is anticipated to witness substantial growth in the coming years.
Scope of the Report
The “Bioprocess Controllers and Automation Systems Market By Type of Controllers (Upstream/Downstream Controller System and Bioprocess Control Software), Scale of Operation (Preclinical/Clinical Operations and Commercial Operations), Mode of Operation (Batch, Fed-Batch and Perfusion), Compatibility with Bioprocessing Systems (Single-Use Systems, and Stainless Steel/Other Systems), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current landscape and the likely future potential of bioprocess controllers and automation systems, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.
In addition to other elements, the study includes:
- A detailed assessment of the overall market landscape of bioprocess controller and automation systems (upstream controllers, downstream controller systems and bioprocess control software) based on a number of relevant parameters, such as scale of operation (lab, clinical and commercial), mode of operation (batch, fed-batch and perfusion), key features (scalability/ease to use, visual data display, remote accessibility, data processing capabilities, built-in system control sensors, expansive I/O compatibility and provisions for alarms/alerts), compatibility with the bioprocessing systems (stirred tank (glass), single use bioreactor, stirred tank (steel), fermenter, rocking motion, chromatography system, tangential flow filtration system), type of system(s) (single-use system and multi-use system) and type of processes controlled (cell cultivation, microbial fermentation, chromatography and filtration). In addition, it presents details of the companies developing bioprocess controller and automation systems, highlighting their year of establishment, company size, and geographical presence.
- A detailed competitiveness analysis of upstream controllers, downstream controller systems and process control software, taking into consideration several relevant parameters, such as the product applicability (scale of operation, processes controlled, mode of operation and stage of bioprocess) and product strength (key features, and compatibility with system).
- Tabulated profiles of the key players providing upstream controllers, downstream controller systems and process control software. Each profile includes an overview of the company, information on the financial performance (if available), product portfolio, recent developments, and an informed future outlook.
- A contemporary market trend analysis, featuring a world map representation to highlight the regional distribution of players engaged in the development of upstream controllers, downstream controller systems and bioprocess control software, along with the information on type of products offered (upstream controllers, downstream controller systems and bioprocess control software). Further, the chapter also presents (a) a heat map representation of upstream controllers, based on compatibility with bioreactor systems, scale of operation and mode of operation, (b) a grid analysis of upstream controllers, based on scale of operation, compatibility with bioreactor systems and processes controlled (c) a grid analysis of downstream controller systems, based on scale of operation, type of systems and key features, (d) an analysis of downstream controller systems, based on mode of operation and application area (e) a grid analysis of bioprocess control software, based on scale of operation, key features and processes controlled and (f) an analysis of bioprocess control software, based on scale of operation and compatibility with bioprocessing systems.
- An in-depth analysis of various patents that have been filed/granted for bioprocess controller and automation systems, till July 2021, highlighting key trends associated with these patents, across type of patents, publication year, application year, issuing authorities involved, type of organizations, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted/filed), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.
- A detailed brand positioning analysis of the key industry players (including upstream controller developers, downstream controller system developers, and bioprocess control software developers), highlighting the current perceptions regarding their proprietary products by taking into consideration several relevant aspects, such as experience of the manufacturer, number of products offered, product diversity, and number of patents published.
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of bioprocess controller and automation systems market. Based on multiple parameters, such as overall bioprocessing equipment market, and adoption rate of automation systems, we have provided an informed estimate of the evolution of the market for the period 2021-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of controllers (upstream controllers, downstream controller system and bioprocess control software), [B] scale of operation (preclinical/clinical operations and commercial operations), [C] mode of operation (batch, fed-batch and perfusion), [D] compatibility with bioprocessing systems (single-use systems, and stainless steel/other systems), and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the report are backed by a deep understanding of key insights generated from both secondary and primary research. The information presented in this study was also influenced by discussions held with senior stakeholders in this industry.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
- Who are the leading players engaged in the development of bioprocess controller and automation systems?
- What are the different application areas where bioprocess controller and automation systems can be used?
- What are the key features of bioprocess controller and automation systems?
- How has the intellectual property landscape of bioprocess controller and automation, evolved over the years?
- What are the key trends within the bioprocess controllers and automation systems market?
- How is the current and future opportunity likely to be distributed across key market segments?
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agilitech
- Amgen
- Andrew Alliance (acquired by Waters)
- Applikon Biotechnology (acquired by Getinge)
- ARTeSYN Biosolutions (acquired by Repligen)
- Automated Control Concepts (ACC)
- Bioengineering
- BIONET
- Bioreactors.net
- BlueSens gas sensor
- Clorox
- CSL
- Curexsys
- Cytiva (acquired by Danaher)
- DISTek
- Duke University
- Eppendorf
- Flotek
- Flownamics
- General Electric (GE)
- Getinge
- GoSilico (acquired by Cytiva)
- Harvard Business School
- ILS Automation
- INFORS HT
- Inscripta
- J. Craig Venter Institute (JCVI)
- LAMBDA Laboratory Instruments
- Lonza
- Massachusetts Institute of Technology (MIT)
- Medtronic
- Merck Millipore
- Novasep
- Pall (acquired by Danaher)
- Parker Hannifin
- PendoTECH
- Pierre Guérin
- Plus Therapeutics (formerly Cytori Therapeutics)
- Princeton University
- Procter & Gamble (P&G)
- Propel Labs
- Repligen
- Roche
- Rockwell Automation
- Sartorius Stedim Biotech
- Securecell
- Sepragen
- Solaris Biotechnology
- Solida Biotech
- SYSBIOTECH
- Terumo Blood and Cell Technologies
- Thermo Fisher Scientific
- University of California
- University of Maryland
- University of Missouri
- Vanderbilt University
- VERDOT Ips²
- WaterSep BioSeparations (acquired by Sartorius)
- Xyleco
Methodology
LOADING...